About This Video
This video is
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that the interim safety and efficacy results from the first 20 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma are as good as or better than Phase 1 data. Additionally, extended Phase 1 survival data was reported.
To view Multimedia News Release go to http://www.prnewswire.com/mnr/pvct/37429/
This website uses Adobe® Flash™ Player 9
Download Flash Now
If you are using Internet Explorer, you will need to restart your browser
after installing Flash.
Adobe and Flash are registered trademarks of Adobe Systems incorporated.
All rights reserved.
